Prostate Cancer

See how Bayer is investigating prostate cancer across the pipeline

Follow the connections from areas of research to investigational compounds and the clinical trials evaluating them.

Prostate Cancer Overview

Bayer’s prostate cancer research spans androgen receptor signaling and targeted radionuclide therapy, representing distinct scientific approaches being investigated across the oncology portfolio.

These programs connect areas of research with compounds and clinical trials across multiple prostate cancer settings.

2 investigational compounds

2 areas of research

10 clinical trials

Compounds

²²⁵Ac felivotide mopaxetan (²²⁵Ac-PSMA-Trillium) (BAY 3563254)

Darolutamide

Radium-223 dichloride (Ra-223)

Areas of Research

Androgen receptor signaling

Targeted radionuclide therapy

Clinical Trials

Tumor Type(s)	Phase	Status	Description	NCT Number
Prostate Cancer	I	Now Enrolling	A Phase 1 Open-label, First-in-human, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ²²⁵Ac-PSMA-Trillium in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) (PAnTHA)	NCT06217822
Prostate Cancer	III	Active, Not Enrolling	Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)	NCT03574571
Prostate Cancer	III	Active, Not Enrolling	Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (DASL-HiCaP)	NCT04136353
Prostate Cancer	III	Active, Not Enrolling	An Open-label, Single Arm, Roll-over Study to Provide Continued Treatment With Darolutamide in Participants Who Were Enrolled in Previous Bayer Sponsored Studies	NCT04464226
Prostate Cancer	III	Active, Not Enrolling	A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide Plus Androgen Deprivation Therapy (ADT) Compared With Placebo Plus ADT in Patients With High-risk Biochemical Recurrence (BCR) of Prostate Cancer	NCT05794906
Prostate Cancer	Non-interventional Study	Active, Not Enrolling	Darolutamide Observational Study in Non-metastatic Castration-resistant Prostate Cancer Patients	NCT04122976
Prostate Cancer	Non-interventional Study	Now Enrolling	A Multicenter, Real-world Study Evaluating the Effectiveness of Darolutamide Plus ADT in Patients Progressing to nmCRPC After Bicalutamide Plus ADT Treatment During nmHSPC Stage	NCT07538843
Prostate Cancer	Non-interventional Study	Now Enrolling	Post-marketing Surveillance Study for Approved Darolutamide Use in Korean Patients	NCT06334120
Prostate Cancer	Non-interventional Study	Now Enrolling	An Observational Study of Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients With Low-volume Metastatic Hormone-sensitive Prostate Cancer	NCT06661122
Prostate Cancer	Non-interventional Study	Active, Not Enrolling	ROAD - Real-World Outcomes of Darolutamide, ADT, With or Without Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer	NCT07344779

Bayer’s Oncology Pipeline Brochure

Explore a comprehensive overview of Bayer's oncology pipeline, including investigational compounds, clinical trials, and areas of research.

Download BrochurePDF (1.45 MB)

The ongoing clinical trials listed on this website represent a comprehensive overview of Bayer's clinical pipeline in Oncology, including Bayer-sponsored research and collaborative research with academic centers, cooperative groups, and other global institutions.